Bonnet-Serrano F, Bertherat J (2018) Genetics of tumors of the adrenal cortex. Endocrine-related Cancer 25:R131–R152. https://doi.org/10.1530/ERC-17-0361

Article  CAS  PubMed  Google Scholar 

Nieman LK, Biller BMK, Findling JW, Newell-Price J, Savage MO, Stewart PM et al (2008) The diagnosis of Cushing’s syndrome: an endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93:1526–1540. https://doi.org/10.1210/jc.2008-0125

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ahn CH, Kim JH, Park MY, Kim SW (2021) Epidemiology and comorbidity of adrenal cushing syndrome: a Nationwide Cohort Study. J Clin Endocrinol Metab 106:e1362–e1372. https://doi.org/10.1210/clinem/dgaa752

Article  PubMed  Google Scholar 

Fassnacht M, Tsagarakis S, Terzolo M, Tabarin A, Sahdev A, Newell-Price J et al (2023) European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the study of adrenal tumors. Eur J Endocrinol 189:G1–42. https://doi.org/10.1093/ejendo/lvad066

Article  PubMed  Google Scholar 

Arlt W, Biehl M, Taylor AE, Hahner S, Libé R, Hughes BA et al (2011) Urine steroid Metabolomics as a Biomarker Tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metabolism 96:3775–3784. https://doi.org/10.1210/jc.2011-1565

Article  CAS  Google Scholar 

Newell-Price J, Bertagna X, Grossman AB, Nieman LK (2006) Cushing’s syndrome. Lancet 367:1605–1617. https://doi.org/10.1016/S0140-6736(06)68699-6

Article  CAS  PubMed  Google Scholar 

Lacroix A (2009) ACTH-independent macronodular adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 23:245–259. https://doi.org/10.1016/j.beem.2008.10.011

Article  CAS  PubMed  Google Scholar 

Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X et al (1990) Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 322:1195–1201. https://doi.org/10.1056/NEJM199004263221705

Article  CAS  PubMed  Google Scholar 

Rubinstein G, Osswald A, Hoster E, Losa M, Elenkova A, Zacharieva S et al (2020) Time to diagnosis in Cushing’s syndrome: a Meta-analysis based on 5367 patients. J Clin Endocrinol Metab 105:dgz136. https://doi.org/10.1210/clinem/dgz136

Article  PubMed  Google Scholar 

Pelsma ICM, Fassnacht M, Tsagarakis S, Terzolo M, Tabarin A, Sahdev A et al (2023) Comorbidities in mild autonomous cortisol secretion and the effect of treatment: systematic review and meta-analysis. Eur J Endocrinol 189:S88–101. https://doi.org/10.1093/ejendo/lvad134

Article  PubMed  Google Scholar 

Bertherat J, Horvath A, Groussin L, Grabar S, Boikos S, Cazabat L et al (2009) Mutations in Regulatory Subunit Type 1A of cyclic adenosine 5′-Monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. J Clin Endocrinol Metabolism 94:2085–2091. https://doi.org/10.1210/jc.2008-2333

Article  CAS  Google Scholar 

Beuschlein F, Fassnacht M, Assié G, Calebiro D, Stratakis CA, Osswald A et al (2014) Constitutive activation of PKA catalytic subunit in adrenal Cushing’s syndrome. N Engl J Med 370:1019–1028. https://doi.org/10.1056/NEJMoa1310359

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gaujoux S, Tissier F, Groussin L, Libé R, Ragazzon B, Launay P et al (2008) Wnt/beta-catenin and 3’,5’-cyclic adenosine 5’-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors. J Clin Endocrinol Metab 93:4135–4140. https://doi.org/10.1210/jc.2008-0631

Article  CAS  PubMed  Google Scholar 

Tissier F, Cavard C, Groussin L, Perlemoine K, Fumey G, Hagneré A-M et al (2005) Mutations of β-Catenin in Adrenocortical tumors: activation of the wnt signaling pathway is a frequent event in both Benign and Malignant Adrenocortical tumors. Cancer Res 65:7622–7627. https://doi.org/10.1158/0008-5472.CAN-05-0593

Article  CAS  PubMed  Google Scholar 

Li FP, Fraumeni JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA et al (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358–5362

CAS  PubMed  Google Scholar 

Li FP, Fraumeni JF (1969) Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 71:747–752. https://doi.org/10.7326/0003-4819-71-4-747

Article  CAS  PubMed  Google Scholar 

Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH et al (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233–1238. https://doi.org/10.1126/science.1978757

Article  CAS  PubMed  Google Scholar 

Wagner J, Portwine C, Rabin K, Leclerc JM, Narod SA, Malkin D (1994) High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst 86:1707–1710. https://doi.org/10.1093/jnci/86.22.1707

Article  CAS  PubMed  Google Scholar 

Pinto EM, Chen X, Easton J, Finkelstein D, Liu Z, Pounds S et al (2015) Genomic landscape of paediatric adrenocortical tumours. Nat Commun 6:6302. https://doi.org/10.1038/ncomms7302

Article  CAS  PubMed  Google Scholar 

Raymond VM, Else T, Everett JN, Long JM, Gruber SB, Hammer GD (2013) Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma. J Clin Endocrinol Metab 98:E119–125. https://doi.org/10.1210/jc.2012-2198

Article  CAS  PubMed  Google Scholar 

Herrmann LJM, Heinze B, Fassnacht M, Willenberg HS, Quinkler M, Reisch N et al (2012) TP53 germline mutations in adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab 97:E476–485. https://doi.org/10.1210/jc.2011-1982

Article  CAS  PubMed  Google Scholar 

Bouaoun L, Sonkin D, Ardin M, Hollstein M, Byrnes G, Zavadil J et al (2016) TP53 variations in human cancers: New lessons from the IARC TP53 database and Genomics Data. Hum Mutat 37:865–876. https://doi.org/10.1002/humu.23035

Article  CAS  PubMed  Google Scholar 

Pinto EM, Billerbeck AEC, Villares MCBF, Domenice S, Mendonça BB, Latronico AC (2004) Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors. Arq Bras Endocrinol Metabol 48:647–650. https://doi.org/10.1590/s0004-27302004000500009

Article  PubMed  Google Scholar 

Mastellaro MJ, Seidinger AL, Kang G, Abrahão R, Miranda ECM, Pounds SB et al (2017) Contribution of the TP53 R337H mutation to the cancer burden in southern Brazil: insights from the study of 55 families of children with adrenocortical tumors. Cancer 123:3150–3158. https://doi.org/10.1002/cncr.30703

Article  CAS  PubMed  Google Scholar 

Custodio G, Taques GR, Figueiredo BC, Gugelmin ES, Oliveira Figueiredo MM, Watanabe F et al (2011) Increased incidence of choroid plexus carcinoma due to the germline TP53 R337H mutation in southern Brazil. PLoS ONE 6:e18015. https://doi.org/10.1371/journal.pone.0018015

Article  CAS  PubMed  PubMed Central  Google Scholar 

Renaux-Petel M, Charbonnier F, Théry J-C, Fermey P, Lienard G, Bou J et al (2018) Contribution of de novo and mosaic TP53 mutations to Li-Fraumeni syndrome. J Med Genet 55:173–180. https://doi.org/10.1136/jmedgenet-2017-104976

Article  CAS  PubMed  Google Scholar 

Henry I, Jeanpierre M, Couillin P, Barichard F, Serre JL, Journel H et al (1989) Molecular definition of the 11p15.5 region involved in Beckwith-Wiedemann syndrome and probably in predisposition to adrenocortical carcinoma. Hum Genet 81:273–277. https://doi.org/10.1007/BF00279003

Article  CAS  PubMed  Google Scholar 

Wilkin F, Gagné N, Paquette J, Oligny LL, Deal C (2000) Pediatric adrenocortical tumors: molecular events leading to insulin-like growth factor II gene overexpression. J Clin Endocrinol Metab 85:2048–2056. https://doi.org/10.1210/jcem.85.5.6589

Article  CAS